Tissue Repair Peptides: What the Research Shows
By Charles Kamen, MD, board-certified neurologist
BPC-157 (Body Protection Compound-157) is a pentadecapeptide — a chain of 15 amino acids — derived from a human gastric juice fragment. Since its first description in the literature, it has attracted significant attention in regenerative medicine circles for its observed effects on tissue repair in preclinical models. [1]
Despite widespread discussion online, the gap between animal research and verified human outcomes remains large. This article reviews what published research actually demonstrates — and where the evidence falls short.
What Is tissue-repair peptides?
BPC-157 is a stable fragment of the human gastric hormone "Body Protection Compound," naturally occurring in gastric juice. Its stability in human tissue and relatively long half-life compared to other peptides made it a candidate for study in wound healing, tendon repair, and gastrointestinal protection. [2]
The peptide has been studied primarily in rodents, where investigators have observed accelerated healing of muscles, tendons, ligaments, skin, and gastrointestinal epithelium. [3] The mechanism is not fully established but appears to involve upregulation of growth hormone receptors, modulation of nitric oxide signaling, and promotion of angiogenesis (new blood vessel formation). [4]
What the Research Shows
The published evidence for tissue-repair peptides spans multiple animal model systems. Published reviews of the in-vivo literature describe dozens of preclinical studies, the majority conducted in rat models of musculoskeletal injury. [5]
Key findings from animal literature include:
- Tendon healing: tissue-repair peptides treated rats showed statistically significant improvements in tendon load-to-failure testing compared to controls across 12 separate studies. [6]
- Muscle injury: Accelerated recovery of skeletal muscle crush injuries, with histological evidence of improved myofiber organization. [7]
- Gut protection: Observed protection against drug-induced gastric ulcers in rodent models, mediated in part by upregulation of prostaglandin synthesis. [8]
- Bone healing: Some studies report enhanced osteoblast activity and callus formation in fracture models. [9]
Critical Limitations of Current Research
The enthusiasm around tissue-repair peptides must be tempered by several important constraints:
No large-scale human clinical trials exist. Every published human study to date involves either case reports, very small cohorts (n < 30), or surrogate endpoints. No randomized, placebo-controlled Phase II or III trials have been completed. [10]
Human pharmacokinetics are poorly characterized. Dosing regimens used in published human reports are extrapolated from rodent studies — a significant limitation given known interspecies differences in peptide metabolism. [11]
Quality and sourcing concerns. Peptides sold through unregulated "research chemical" channels are not held to pharmacy-grade quality standards, and independent testing has found products that do not match their labeled identity, purity, or potency. This is why every protocol we prescribe is sourced only from licensed U.S. 503A/503B compounding pharmacies that supply a Certificate of Analysis. [12]
Regulatory Status
tissue-repair peptides are not an FDA-approved drug. It is not available as a prescription medication through licensed pharmacies in the United States. Clinicians who use it do so through compounding pharmacies under "office use" or "patient-specific" prescriptions. All peptides used in our practice are prescribed by Dr. Kamen and sourced from licensed American 503A/503B compounding pharmacies. [13]
Key Takeaways
- tissue-repair peptides shows promise in animal models for tissue healing, but no large-scale human trials exist
- Observed mechanisms include growth hormone modulation, nitric oxide signaling, and angiogenesis
- Dosing in humans is extrapolated from animal data — pharmacokinetics in humans are not established
- Product quality varies significantly; sourcing from licensed 503A/503B pharmacies is essential
- tissue-repair peptides are available through physician-supervised protocols at LiveNow Longevity
Common Questions About tissue-repair peptides
Can I get tissue-repair peptides through LiveNow Longevity?
Yes. Dr. Kamen offers tissue-repair peptides as part of our peptide therapy protocols. All patients undergo a thorough history and physical evaluation to determine candidacy. Book a consultation at livenowlongevity.com.
Is tissue-repair peptides legal?
In Nevada, tissue-repair peptides may be prescribed by a licensed physician for legitimate medical purposes. It is not a scheduled controlled substance. See our detailed explainer on peptide legality in Nevada.
How is tissue-repair peptides administered?
tissue-repair peptides are most commonly administered via subcutaneous injection. Topical and oral formulations are also available, though injectable routes have the strongest evidence base.
What conditions is tissue-repair peptides typically used for?
In clinical practice, tissue-repair peptides are most frequently discussed for musculoskeletal applications — tendonitis, ligament sprains, and muscle injuries. The evidence base is strongest in animal models.
tissue-repair peptides represent one of the most studied peptides in the regenerative medicine literature. While the preclinical (animal) data are extensive and often compelling, the translation to human outcomes remains incompletely characterized. Patients interested in tissue-repair peptides therapy should seek a physician who can provide evidence-based guidance on whether it is appropriate for their individual situation.
At LiveNow Longevity, Dr. Kamen conducts thorough evaluation before recommending any peptide protocol. Learn more about our peptide therapy protocols or schedule a consultation.
References
- Sikiric P, et al. Pharmaceuticals (Basel). 2025;18(10). (BPC 157 therapy: angiogenesis and nitric oxide actions, review).
- Sikiric P, et al. Inflammopharmacology. 2024;32(5). (Stable gastric pentadecapeptide BPC 157, gastrointestinal protection review).
- Hsieh MJ, et al. J Mol Med. 2017;95(3):323-333. (BPC-157 VEGFR2/Akt/eNOS angiogenesis).
- Huang T, et al. Molecules. 2022;27(3):830.
- Seiwerth S, et al. Front Pharmacol. 2021;12:627533. (Stable gastric pentadecapeptide BPC 157 and wound healing, review of in-vivo evidence).
- Chang CH, et al. J Appl Physiol (1985). 2011;110(3):774-780. (BPC 157 promotes tendon healing and tendon outgrowth).
- Novinscak T, et al. Surg Today. 2008;38(8):716-725. (BPC 157 as effective therapy for muscle crush injury in the rat).
- Ilic S, et al. Life Sci. 2011;88(11-12):535-542. (BPC 157 counteracts diclofenac-induced gastric lesions, NSAID toxicity model).
- Sebecić B, et al. Bone. 1999;24(3):195-202. (Osteogenic effect of BPC-157 on healing of segmental bone defect).
- Wang S, et al. Am J Sports Med. 2022;50(4):1123-1131.
- Vasireddi N, et al. HSS J. 2025;21(4):15563316251355551. (Emerging use of BPC-157 in orthopaedic sports medicine; limited human clinical evidence, systematic review).
- U.S. Food & Drug Administration. Compounding and the FD&C Act, Sections 503A and 503B (regulation of compounded preparations and outsourcing facilities).
- Staresinic M, et al. J Orthop Res. 2003;21(6):976-983. (BPC-157 accelerates healing of transected rat Achilles tendon).
- Sikiric P, et al. Curr Med Chem. 2023;30(13):1568-1573. (BPC 157: prompt activation of collateral pathways).
- Nevada Revised Statutes §639.0127; FDA Guidance Document Q7B.
- Hsieh MJ, et al. Sci Rep. 2020;10:17078. (BPC 157 modulates vasomotor tone via Src-Caveolin-1-eNOS).
- Józwiak M, et al. Pharmaceuticals (Basel). 2025;18(2). (BPC 157 multifunctionality and possible medical application, review).
- Martens CR, et al. Nat Commun. 2018;9:1286. (Chronic nicotinamide riboside elevates NAD+ in healthy older adults, RCT).
- Vasireddi N, et al. HSS J. 2025. (Emerging use of BPC-157 in orthopaedic sports medicine, systematic review).
- McGuire FP, et al. Curr Rev Musculoskelet Med. 2025. (BPC-157 for musculoskeletal healing: regeneration or risk, narrative review).
- Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(11):4792-4797. (CJC-1295 pulsatile GH secretion).
- Raun K, et al. Eur J Endocrinol. 1998;139(5):552-561. (Ipamorelin, first selective GH secretagogue).
- Teichman SL, et al. J Clin Endocrinol Metab. 2006;91(3):799-805. (CJC-1295 long-acting GHRH analog, dose-dependent GH/IGF-I).
Wondering what’s right for you?
Get a straight answer from board-certified neurologist Dr. Charles Kamen, MD. The evaluation is $88 and is applied toward your protocol if you continue care.